167626-25-7

Usage

InChI:InChI=1/C11H11N3O2/c1-2-16-11(15)9-3-5-10(6-4-9)14-7-12-13-8-14/h3-8H,2H2,1H3

Upstream product

• 16114-05-9 N,N'-bis(dimethylaminomethylene)hydrazine 
• 94-09-7 p-aminoethylbenzoate 
• 16227-06-8 {N'-[(dimethylamino)methylene]-N,N-dimethylhydrazonoformamide dihydrochloride} 
• 288-88-0 1,2,4-Triazole 
• 451-46-7 4-fluorobenzoic acid ethyl ester 

Downstream Products

• 157069-48-2 4-(4’-carboxyphenyl)-1,2,4-triazole 

Relevant academic research and scientific papers

Reaction of aminobenzoate esters with N,N′-dimethylformamide azine dihydrochloride: Crucial influence of intramolecular hydrogen bonding for the formation of 1,2,4-triazoles

The reaction of N,N′-dimethylformamide azine (DMFA) or its dihydrochloride derivative (DMFA·2HCl) with o-RO(O)CC6H 4NH2 (R = Me, Et) leads to co-crystallization products o-RO(O)CC6H4NH2·DMFA (R = Me, Et), while the same reaction of DMFA·2HCl with m- and p-RO(O)CC6H 4NH2 (R = Me, Et) provides the corresponding 4-substituted 1,2,4-triazoles (1-4). Reaction of the same m- and p-substituted amines with DMFA has failed, while addition of a few drops of HCl or HNO3 in this reaction mixture has allowed us to obtain the corresponding triazole derivatives. Thus, the direct transamination reaction with the formation of triazoles 1-4 is catalysed by acidic catalysts. Molecular structures of DMFA, o-EtO(O)CC6H4NH2·DMFA and 3 were elucidated by X-ray diffraction. The Royal Society of Chemistry 2012.

BENZOXAZOLE DERIVATIVES

It is intended to provide a benzoxazole derivative or a pharmaceutically acceptable salt or solvate thereof which is useful in the early diagnosis of a conformation disease; a composition or a kit containing the same for diagnosing a conformation disease; a medical composition for ttreating and/or preventing a conformation disease; and so on.

Sulfonamide derivatives, their production and use

The present invention provides compounds which specifically inhibit FXa, which are effective when orally administered and which are useful as a safe medicine for the prevention or treatment of diseases caused by thrombus or infarction. Compounds of this invention are piperazinones of the formula: wherein R1is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; the ring A is an optionally substituted divalent nitrogen-containing heterocyclic group, in addition to being substituted by the group of the formula: and the group of the formula: Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent heterocyclic group; X is a direct bond or an optionally substituted alkylene chain; Z is (1) an amino group substituted with an optionally substituted hydrocarbon group, (2) an optionally substituted imino group or (3) an optionally substituted nitrogen-containing heterocyclic group; provided that when X is a direct bond and Z is an optionally substituted 6-membered nitrogen-containing aromatic heterocyclic group, Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent unsaturated heterocyclic group; or a salt thereof.

Peripheral vasodilating agent containing piperidine derivative as active ingredient

The present invention relates to novel peripheral vasodilating agents characterized by each containing as an active ingredient, a piperidine derivative or pharmaceutically acceptable salt thereof having excellent peripheral vasodilating activity. Said pip